Your Opportunity to Invest in Excellence

Through exclusive license agreements with the National University of Singapore, GENY has unique access to the research and development pipeline of a full suite of highly potent antibodies and engineered proteins.

With freedom to operate, GENY’s business model generates income streams from out-licensing IP, as well as generating income from sales through developing its own diagnostics.

A close working relationship with NUS researchers, together with our strategic location at co11ab incubator situated in NTU’s Clinical Sciences Building in the heart of Novena’s health hub, means GENY creates value for investors and reduces risk by maintaining a lean core, benefitting from in-house expertise and opportunities for government supported funding to move projects from the laboratory through the early stages of commercialisation. GENY is seeking private investment to advance its projects and take its diagnostics all the way to market.

Using this model, GENY achieved IVD registration in the EU for ImTracker, a laboratory test for immunity to infection by viral variants of SARS-CoV-2, the virus that causes Covid-19. This approach will be used to develop our first-in-class dengue serotype point of care (POC) diagnostic test.

If you would like to learn more about investment opportunities with GENY Biologics, please click below.